Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity
- Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity Endocr Rev
Insulin Resistance & Diabetes
Epidemiology Landscape and Impact of Overweight and Obesity in Adults: Multi-country Results from the IMPACT-O Study
- Artime E, Spaepen E, Zimner-Rapuch S, Lampropoulou A, Adam A, Lin X, Shang M, Seager S, Le Roux CW, Dicker D. Epidemiology Landscape and Impact of Overweight and Obesity in Adults: Multi-country Results from the IMPACT-O Study Advances in Therapy
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD; REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes N Engl J Med
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
- Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities The Journal of Peptide Science
Metabolic/Bariatric Surgery is Safe and Effective in People with Obesity, Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Cohen RV, Azevedo MA, Le Roux CW, Caldeon LP, Luque A, Fayad DA, Petry TBZ. Metabolic/Bariatric Surgery is Safe and Effective in People with Obesity, Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Obes Surg
Author Correction: Subclassification of obesity for precision prediction of cardiometabolic diseases
- Coral DE, Smit F, Farzaneh A, Gieswinkel A, Tajes JF, Sparsø T, Delfin C, Bauvin P, Wang K, Temprosa M, De Cock D, Blanch J, Fernández-Real JM, Ramos R, Ikram MK, Gomez MF, Kavousi M, Panova-Noeva M, Wild PS, van der Kallen C, Adriaens M, van Greevenbroek Author Correction: Subclassification of obesity for precision prediction of cardiometabolic diseases Nat Med
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial
- le Roux CW, Steen O, Lucas KJ, Ekinci EI, Startseva E, Unseld A, Hussain SA, Hennige AM. Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial Diabetes Obes Metab
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes
- Saravanan P, Bell H, Braae UC, Collins E, Deinega A, Dhatariya K, Machell A, Trent A, Strzelecka A. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes Adv Ther
Metabolic/Bariatric Surgery is Safe and Effective in People with Obesity, Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Cohen RV, Azevedo MA, Le Roux CW, Caldeon LP, Luque A, Fayad DA, Petry TBZ. Metabolic/Bariatric Surgery is Safe and Effective in People with Obesity, Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Obes Surg